non-alcoholic fatty liver disease

(redirected from Non-alcoholic steatohepatitis)

non-alcoholic fatty liver disease

A fatty liver lacking histologic features typically associated with alcohol abuse, which primarily affects overweight women. With time, patients develop portal changes such as interface hepatitis, increased portal inflammation and fibrosis, and autoantibodies.
 
Risk factors
Diabetes, obesity, hypertension, gallstones, hyperlipidaemia, hypertriglyceridaemia.

Pathogenesis
Uncertain; possibly oxidative stress and lack of antioxidants.

Non-alcoholic fatty liver disease types
• Steatosis;
• Steatosis with inflammation;
• Non-alcoholic steatohepatitis (NASH);
• Cirrhosis.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
(NASDAQ: HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ('NASH') and chronic viral infection, today announced that management will present an update on the Company's business at the H.
M2 PRESSWIRE-August 29, 2019-: Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market 2019-2028: Escalating Market Penetration for NASH Major Drugs / Progressing NASH Diagnosis Methods and Biomarkers
Non-alcoholic steatohepatitis is a metabolic disease with no clear disease origin that is quickly becoming a worldwide epidemic.
Galectin Therapeutics announced it has submitted for assessment the Phase 3 protocol for using belapectin for the treatment of compensated non-alcoholic steatohepatitis cirrhosis without esophageal varices.
Spitfire was set up by Velocity Pharmaceutical Development and Dr John Nestor for the development of SP-1373, a GLP-1/Glucagon receptor co-agonist to treat non-alcoholic steatohepatitis (NASH).
MONT-SAINT-GUIBERT, Belgium, May 9, 2019 -- Promethera Biosciences SA announced the dosing of a first patient in a Phase 2a clinical study for the company's HepaStem development program in patients with late stage non-alcoholic steatohepatitis (NASH).
Biopharmaceutical company 3-V Biosciences Inc said on Tuesday that its has recently dosed its first patient under its Phase 2 clinical trial of the FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code:ASC40) in patients with non-alcoholic steatohepatitis (NASH).
[1] Ludwig et al introduced term non-alcoholic steatohepatitis to describe liver disease that is histologically indistinguishable from alcoholic hepatitis but occurs in persons who do not consume excess alcohol.
The agreement is related to an investigational compound targeting the pituitary adenylate cyclase receptor 1 (PAC1) in non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and various other gastrointestinal and liver diseases.
Known as non-alcoholic steatohepatitis (NASH), it eventually progresses to cirrhosis or liver cancer, especially in those with obesity or Type 2 diabetes.
The condition, known as non-alcoholic steatohepatitis, or NASH, is a more advanced form of fatty liver disease, which features inflammation of the liver.

Full browser ?